Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Ref

Indication
Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia; B-cell Lymphoma

Other upcoming events for NRIX

Patent ExpiryPatent/Exclusivity Expiry: ESOMEPRAZOLE MAGNESIUM

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Ref — NRIX Phase 3 Readout | BioSniper